TrialSignal transduction and targeted therapy2021

Safety and immunogenicity of a recombinant COVID-19 vaccine (Sf9 cells) in healthy population aged 18 years or older: two single-center, randomised, double-blind, placebo-controlled, phase 1 and phase 2 trials.

Fan-Yue Meng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.